Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
Unicycive Therapeutics announced its full year 2025 financial results and provided a business update highlighting the FDA's acceptance of the New Drug Application resubmission for oxylanthanum carbonate (OLC), an investigational treatment for hyperphosphatemia in patients with chronic kidney disease on dialysis. The FDA has set a PDUFA target actio…